Select Publications

Journal articles

Yates WB; McCluskey PJ; Fraser CL, 2022, 'Neuro-ophthalmological manifestations of sarcoidosis', Journal of Neuroimmunology, vol. 367, pp. 577851 - 577851, http://dx.doi.org/10.1016/j.jneuroim.2022.577851

Dunn HP; Browning SD; Thomson D; Yates WB; McCluskey P; Keay L; White AJ; Fraser CL, 2022, 'Impact on patient management of non-mydriatic fundus photography compared to direct ophthalmoscopy in a regional Australian emergency department', EMA - Emergency Medicine Australasia, vol. 34, pp. 186 - 193, http://dx.doi.org/10.1111/1742-6723.13845

Wakefield D; Yates W; McCluskey P, 2022, 'Is There a Safe Systemic Corticosteroid Dose?', Ocular Immunology and Inflammation, vol. 30, pp. 479 - 480, http://dx.doi.org/10.1080/09273948.2022.2027467

Yates WB; Mammo Z; Simunovic MP, 2021, 'Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis', Canadian Journal of Ophthalmology, vol. 56, pp. 355 - 363, http://dx.doi.org/10.1016/j.jcjo.2021.01.017

Shao EH; Yates WB; Ho I-V; Chang AA; Simunovic MP, 2021, 'Endophthalmitis: Changes in Presentation, Management and the Role of Early Vitrectomy.', Ophthalmol Ther, vol. 10, pp. 877 - 890, http://dx.doi.org/10.1007/s40123-021-00406-6

Yates WB; Nothling S; Lawlor M, 2019, 'Optic Perineuritis Due to Tuberculosis', JOURNAL OF NEURO-OPHTHALMOLOGY, vol. 39, pp. 257 - 259, http://dx.doi.org/10.1097/WNO.0000000000000717

Yates WB; Chiong F; Zagora S; Post JJ; Wakefield D; McCluskey P, 2019, 'Ocular toxoplasmosis in a tertiary referral center in Sydney Australia-clinical features, treatment, and prognosis', Asia-Pacific Journal of Ophthalmology, vol. 8, pp. 280 - 284, http://dx.doi.org/10.1097/APO.0000000000000244

Ong APC; Angbue Te N; Zagora SL; Symes RJ; Yates W; Chang AA; McCluskey PJ; Simunovic MP, 2019, 'Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora', Clinical and Experimental Ophthalmology, vol. 47, pp. 57 - 62, http://dx.doi.org/10.1111/ceo.13345

Lee JTL; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL, 2018, 'Adalimumab for the treatment of refractory active and inactive non-infectious uveitis', British Journal of Ophthalmology, vol. 102, pp. 1672 - 1678, http://dx.doi.org/10.1136/bjophthalmol-2017-311234

Zagora SL; Symes R; Yeung A; Yates W; Wakefield D; McCluskey PJ, 2017, 'Etiology and Clinical Features of Ocular Inflammatory Diseases in a Tertiary Referral Centre in Sydney, Australia', Ocular Immunology and Inflammation, vol. 25, pp. S107 - S114, http://dx.doi.org/10.1080/09273948.2016.1247871

Yates W; McCluskey P; Wakefield D, 2017, 'Long-term immunosuppressive therapy for inflammatory eye disease–the link between systemic treatment, cardiovascular risk and disease?', Expert Review of Ophthalmology, vol. 12, pp. 321 - 330, http://dx.doi.org/10.1080/17469899.2017.1349610

Wakefield D; Yates W; Amjadi S; McCluskey P, 2016, 'HLA-B27 Anterior Uveitis: Immunology and Immunopathology', Ocular Immunology and Inflammation, vol. 24, pp. 450 - 459, http://dx.doi.org/10.3109/09273948.2016.1158283

Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D, 2015, 'Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: A tertiary referral cohort study', Ophthalmology, vol. 122, pp. 265 - 273, http://dx.doi.org/10.1016/j.ophtha.2014.08.024

Yates WB; McCluskey PJ; Wakefield D, 2013, 'Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?', Journal of Ophthalmic Inflammation and Infection, vol. 3, pp. 1 - 9, http://dx.doi.org/10.1186/1869-5760-3-48


Back to profile page